CYP7A1 Inhibitors
3 drugsAbout CYP7A1
CYP7A1, or cholesterol 7-alpha-hydroxylase, is a crucial enzyme in bile acid synthesis. It catalyzes the first and rate-limiting step in the conversion of cholesterol to bile acids in the liver, playing a vital role in cholesterol homeostasis and lipid metabolism.
CYP7A1's central role in a critical metabolic pathway makes it a significant drug target. Currently, there is no genetic evidence available linking CYP7A1 to specific diseases, suggesting potential risk in pursuing this target.
CYP7A1 is targeted by 3 FDA-approved small molecule drugs: LIVDELZI, CHENODIOL, and CTEXLI. These drugs, developed by Gilead Sciences, LGM PHARMA, and MIRUM, are used in various therapeutic areas.
Top CYP7A1 Drugs
The competitive landscape includes Gilead Sciences, LGM PHARMA, and MIRUM, each with an approved drug.
Low market concentration suggests opportunities for new entrants, but also highlights potential challenges in differentiation.
CYP7A1 Drug Modality Landscape
Modalities
Routes of Administration
CYP7A1 is amenable to small molecule drugs, with oral options available for convenient dosing.
Exploring alternative modalities like antibodies or gene therapies could provide a competitive advantage.
CYP7A1 Clinical Trials 7 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on CYP7A1. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 2 | 2 | 0 | 0 | 100% |
| Phase 2 | 4 | 0 | 2 | 2 | 0% |
| Phase 3 | 1 | 0 | 0 | 1 | - |
Top Sponsors
By Modality
Top Conditions
Top Drugs
CYP7A1 Drug Approval Timeline (2009 - 2025)
The first CYP7A1-targeting drug was approved in 2009, with the most recent approval in 2025, spanning 17 years.
The recent approval suggests renewed interest in CYP7A1, but also indicates a potentially saturated market.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 3 companies competing
- • Market share by company
Full Drug Portfolio
- • All 3 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 3-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 2 (1 company)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on CYP7A1. A trial counts if an approved drug acting on CYP7A1 is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.